As expected, the platelet ADP receptor P2Y12 antagonist clopidogrel in combination with ASA did not show any effect on TF-triggered thrombin generation on phospholipids in the absence of platelets (PFP) compared to ASA monotherapy in the same patients with PAD, whereas the direct FXa inhibitor rivaroxaban in combination with ASA clearly prolonged the lag time and reduced the thrombin peak and the generated thrombin over time (ETP) compared to ASA monotherapy and ASA plus clopidogrel therapy (Figure 2). The gene discussed is TF; the disease is peripheral arterial disease.